Galapagos to Acquire CellPoint and AboundBio

Galapagos NV has entered into agreements to acquire CellPoint and AboundBio, advancing Galapagos into next-generation cell therapy and expanding its portfolio and capabilities.

The acquisition of CellPoint and AboundBio provides access to an innovative, scalable, decentralized and automated point-of-care cell therapy supply model, as well as a next-generation therapeutic platform entirely based on human antibodies. The goal is to expand the current market for CAR-T therapies and provide additional and improved treatment options.

CellPoint has developed, in a strategic collaboration with Lonza, a new point-of-care supply model, which offers the potential for efficient 7-day delivery of CAR-T therapies and avoids complex logistics, meeting thus to the significant limitations of current CAR-Ts. T treatments. The platform consists of CellPoint’s end-to-end xCellit workflow monitoring and management software and Lonza’s Cocoon system, a closed, automated manufacturing platform for cell and gene therapies.

Clinical studies with the CellPoint decentralized supply model have been approved by regulatory authorities in Belgium, Spain and the Netherlands. Two Phase 1/2a studies in rLNHL and rRLL with CD19 CAR-T product candidate are currently underway with results expected in 1H23, providing the opportunity for rapid clinical validation of the point-of-care supply model. CAR-T service. As a next step, the goal is to leverage CellPoint’s platform for novel CAR-Ts from AboundBio’s fully human antibody library and biologic drug discovery and engineering capabilities, with the aim of providing three further next-generation differentiated CAR-T candidates. at the clinic over the next three years.

“With the transactions announced today, we are positioning ourselves as a potential innovator in CAR-T, while building a strong foundation from which we can drive continued innovation for patients with advanced cancers who need new treatment options. Our goal is to bring three next-generation differentiated CAR-T candidates into the clinic over the next three years,” said Paul Stoffels, MD, CEO of Galapagos. “This is a first key step in our strategic transformation to accelerate and diversify our pipeline with the aim of creating short and long-term value through targeted external growth. We continue to explore other business development opportunities to further leverage our internal capabilities and renew our portfolio, and expect to provide a detailed update on our business strategy and portfolio later this year. . With the support of our collaboration partner Gilead, we warmly welcome the CellPoint and AboundBio teams to Galapagos, and together we look forward to bringing potentially transformational medicines to patients around the world.


About Author

Comments are closed.